Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 472 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Testing Clear all
Completed No phase listed Observational

Outcomes of Education and Counseling for BRCA1 Testing

NCT00001468
View directory record Official record
Conditions
Breast Neoplasms, Ovarian Neoplasms
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 10:26 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy

NCT04989504
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Best Practice, Wound Dressing Material, Quality-of-Life Assessment, Questionnaire Administration
Other · Device
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
49
States / cities
Marysville, California • Truckee, California • Frankford, Delaware + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 2 Interventional Results available

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

NCT03659136
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Xentuzumab, Placebo, Everolimus, Exemestane
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
16
States / cities
Chandler, Arizona • Goodyear, Arizona • Beverly Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

NCT00005617
View directory record Official record
Conditions
Melanoma
Interventions
dendritic cell-MART-1 peptide vaccine, leukapheresis
Biological · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 22, 2026, 10:26 AM EDT
Recruiting Phase 1 Interventional

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic NUT Carcinoma, Unresectable Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable NUT Carcinoma
Interventions
Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skin Sensitization Test (Modified Draize-95 Test)

NCT03886987
View directory record Official record
Conditions
Skin Sensitisation
Interventions
Blue Non Sterile Powder Free Nitrile Examination Gloves
Device
Lead sponsor
Central Medicare Sdn. Bhd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 22, 2026, 10:26 AM EDT
Terminated No phase listed Observational

Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients

NCT00652678
View directory record Official record
Conditions
Abnormalities, Radiation-Induced
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
48 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 22, 2026, 10:26 AM EDT
Recruiting No phase listed Observational

CtDNA Based MRD Testing for NAC Monitoring in TNBC

NCT06230185
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Interventions
Not listed
Lead sponsor
Personalis Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 22, 2026, 10:26 AM EDT
Active, not recruiting Not applicable Interventional

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

NCT02276443
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis, Lymph Node Biopsy, Ultrasonography
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
5
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Not applicable Interventional

Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation

NCT04046731
View directory record Official record
Conditions
Allergy
Interventions
Skin Testing
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Not applicable Interventional

Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer

NCT02400060
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage 0 Breast Cancer
Interventions
Telephone-Based Intervention, Survey Administration, Laboratory Biomarker Analysis
Behavioral · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Goldsboro, North Carolina • Winston-Salem, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 22, 2026, 10:26 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

NCT05856526
View directory record Official record
Conditions
Netherton Syndrome
Interventions
Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection, Placebo matching to spesolimab - solution for injection
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Rancho Santa Margarita, California • New Haven, Connecticut • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 22, 2026, 10:26 AM EDT
Terminated Phase 2 Interventional Results available

Personalized Treatment Selection for Metastatic Breast Cancer

NCT00780676
View directory record Official record
Conditions
Breast Cancer
Interventions
Dasatinib, AZD6244
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 22, 2026, 10:26 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome

NCT01609062
View directory record Official record
Conditions
Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
Interventions
BMN 110
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Oakland, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

HRIPT for Collagen Dressing

NCT06283173
View directory record Official record
Conditions
Skin Sensitisation
Interventions
ColActive Plus Collagen Matrix Dressing
Device
Lead sponsor
Covalon Technologies Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 22, 2026, 10:26 AM EDT
Recruiting Not applicable Interventional

Safety, Efficacy and Preventative Effect of a Head Lice Product (X92001483) vs. Nix Creme Rinse (1% Permethrin).

NCT07660354
View directory record Official record
Conditions
Lice; Head Lice
Interventions
Medical Device (X92001483)
Device
Lead sponsor
Oystershell NV
Industry
Eligibility
1 Year and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Maitland, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Topical Antimicrobial Effectiveness Testing

NCT01314703
View directory record Official record
Conditions
Antimicrobial Effectiveness
Interventions
ChloraPrep One-Step, 70% isopropyl alcohol
Drug
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Sterling, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

An 18-week Study to Evaluate a Test Product With a Marketed Prescription Product

NCT07136766
View directory record Official record
Conditions
Hyperpigmentation
Interventions
Facial Toner, Placebo Toner
Drug · Other
Lead sponsor
Good Molecules, LLC
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Challenges Without Prior Skin Testing

NCT03158831
View directory record Official record
Conditions
Drug Hypersensitivity, Penicillin Allergy, Antibiotic Allergy
Interventions
Placebo-Controlled Graded Drug Challenge
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
7 Years and older
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 22, 2026, 10:26 AM EDT
Recruiting Phase 1 Interventional

A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo

NCT06625177
View directory record Official record
Conditions
Vitiligo
Interventions
TEV-53408
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Fremont, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

NCT03239145
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Pembrolizumab, Trebananib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 22, 2026, 10:26 AM EDT
Completed No phase listed Observational Results available

Clinical Evaluation of the Sentosa SA HSV1/2 Qualitative PCR Test

NCT02685956
View directory record Official record
Conditions
Herpes Simplex
Interventions
Vela Sentosa SA HSV1/2 Qualitative PCR Test
Device
Lead sponsor
Vela Diagnostics
Industry
Eligibility
Not listed
Enrollment
2,295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Tampa, Florida • Springfield, Massachusetts • Royal Oak, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2020 · Synced Oct 22, 2026, 10:26 AM EDT
Not listed Phase 4 Interventional

Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy

NCT02270970
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
belimumab
Biological
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
16 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin - Chameleon

NCT02737618
View directory record Official record
Conditions
Dermal Irritation
Interventions
Trojan "Chameleon" Personal Lubricant
Device
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 22, 2026, 10:26 AM EDT